EUVIMEDEUVIMED entdecken
Crossref

A physiologically based pharmacokinetic (PBPK) model describing the kinetics of a commercial mixture α-, β-, and γ-hexabromocyclododecane exposure in mice

Claude Emond iD, Michael J DeVito, Linda S Birnbaum

Archives of Toxicology · 2025

DOI: 10.1007/s00204-024-03939-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Toxicology, 2025. Verfasst von Claude Emond und 2 weiteren Autor:innen. Beteiligte Einrichtung: BioSimulation Consulting Inc., Crabtree, QC, Canada. claude.emond@biosmc.com. Hauptthemen laut MEDLINE: Hydrocarbons, Brominated, Flame Retardants, Models, Biological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hexabromocyclododecane (HBCD) is a brominated flame retardant, that is added, but not chemically bonded, to consumer products. HBCD is sold as a commercial-grade HBCD mixture containing three major stereoisomers: alpha (α), beta (β), and gamma (γ), with relative amounts of 12% for α-HBCD, 6% for β-HBCD, and 82% for γ-HBCD. HBCDs are widely measured in the environment and in biological matrices. The toxicological effects of its exposure in humans are not clearly understood. A recent reassessment pointed out potential thyroid disruption as a primary effect. This current work aims to update a physiologically based pharmacokinetic (PBPK) model for γ-HBCD in C57BL/6 mice and incorporate equations and codes for α-HBCD and β-HBCD isomers and simulate them as a mixture. Physiological parameters were taken from the literature, calculated based on the log Kow or optimized with the dataset. The elimination of HBCDs in urine and feces was optimized to reflect the percent dose excreted, as published in the literature. Compared with data from the literature for α-HBCD, β-HBCD, and γ-HBCD in multiple tissues, the model simulations accurately described the pharmacokinetics of HBCDs in the mouse. The utility of the model was demonstrated by predicting blood concentrations from three studies in adult mice evaluating dopaminergic changes in the brain. Although this PBPK model for the mixture explicitly describes α-HBCD, β-HBCD, and γ-HBCD as individual exposures, but also as a mixture, more experimental data with commercial HBCD mixtures is still needed to improve the model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydrocarbons, BrominatedFlame RetardantsModels, BiologicalAnimalsMice, Inbred C57BLMiceMaleTissue Distribution

Stichwörter der Autor:innen

HBCDHBCDsMixturePBPKPharmacokineticsToxicityα-HBCDβ-HBCD

Substanzen

hexabromocyclododecaneHydrocarbons, BrominatedFlame Retardants

Autor:innen und Institutionen

  • BioSimulation Consulting Inc., Crabtree, QC, Canada. claude.emond@biosmc.com.
  • School of Public Health, Department of Environmental and Occupational Health, University of Montreal, Montreal, QC, Canada. claude.emond@biosmc.com.
  • Center for Computational Toxicology and Exposure, Chemical Characterization and Exposure Division, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA.
  • Scientist Emeritus, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.

ORCID-Profile: Claude Emond

Förderung

  • NIH HHS
  • NIH

Zitieren

APA

Emond, C., DeVito, M. J., & Birnbaum, L. S. (2025). A physiologically based pharmacokinetic (PBPK) model describing the kinetics of a commercial mixture α-, β-, and γ-hexabromocyclododecane exposure in mice. Archives of Toxicology. https://doi.org/10.1007/s00204-024-03939-4

Vancouver

Emond C, DeVito MJ, Birnbaum LS. A physiologically based pharmacokinetic (PBPK) model describing the kinetics of a commercial mixture α-, β-, and γ-hexabromocyclododecane exposure in mice. Archives of Toxicology. 2025. doi:10.1007/s00204-024-03939-4

BibTeX
@article{Emond2025,
  author = {Emond, Claude and DeVito, Michael J and Birnbaum, Linda S},
  title = {A physiologically based pharmacokinetic (PBPK) model describing the kinetics of a commercial mixture α-, β-, and γ-hexabromocyclododecane exposure in mice},
  journal = {Archives of Toxicology},
  year = {2025},
  doi = {10.1007/s00204-024-03939-4}
}
Kostenlos starten →